Devlin, N., Shah, K., Mulhern, B., Pantiri, K. and van Hout, B.
Standard methods for eliciting the preference data upon which value sets are based (e.g. time trade-off, standard gamble) generally have in common an aim to ‘uncover’ the preferences of survey respondents by asking them to evaluate a sub-set of health states. The responses are then used to infer their preferences over all possible dimensions and levels. An alternative approach is to ask respondents directly about the relative importance to them of the dimensions, levels and interactions between them
Questions of happiness and well-being have increasingly been drawing the attention of health economists, with the understanding that its measures approximate quality of life, or at any rate is one of its major components. Happiness in surveys is typically reported as a rating scale.
Hampson, G., Lichten, C., Berdud, M., Pollitt, A., Mestre-Ferrandiz, J., Sussex, J., and Towse, A.
The Oxford Biomedical Research Centre (BRC) was established in April 2007. OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC since its inception.
Cubi-Molla, P., Shah, K.K., Garside, J., Herdman, M. and Devlin, N.
Several studies have found differences in health state values by age. We investigate whether and how age affects respondents’ Time Trade-Off (TTO) and Visual Analogue Scale (VAS) valuations of hypothetical EQ-5D health states using data from the 1993 MVH UK valuation study.
Mulhern, B., Feng, Y., Shah, K., van Hout, B., Janssen, B., Herdman, M. and Devlin, N.
Three EQ-5D value sets (the EQ-5D-3L, crosswalk and EQ-5D-5L) are now available for cost utility analysis in the UK and/or England. The value sets’ characteristics differ, and it is important to systematically assess the implications of these differences for the value generated. The aim of this paper is to compare the characteristics of the three value sets. In this Research Report we analyse and compare the predicted values from each of the three value sets, and also compare EQ-5D-3L and EQ-5D-5L data from patients who completed both measures.
Marsden, G., Towse, A., Pearson, S.D., Dreitlein, B. and Henshall, C.
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and value. Special attention is given to pricing and payment mechanisms, including new approaches to payment based on long-term amortization of initial costs.
The aim of this paper is to consider what normative arguments might exist for advocating the use of any given measure of the average in the context of health state values. We begin by providing examples of the importance and implications of the choice of the measure of central tendency in stated preference studies (including both EQ-5D values and corresponding issues in the willingness to pay literature).
This Research Paper explores decisions by the National Institute for Health and Care Excellence (NICE) that new technologies are to be recommended in line with clinical practice (RiLCP). The authors qualitatively assess documentation associated with RiLCP decisions to create a framework to describe common themes, and assess the level of patient access associated with each RiLCP decision.
Garau, M., Marsden, G., Devlin, N., Amedeo Mazzanti, N. and Profico, A.
Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.
Fischer, A., Hernandez-Villafuerte, K., Latimer, N., and Henshall, C.
This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and interviews involving people from a regulatory agency (EMA) a “payer” organisation (NICE), academics, and from the member organisations comprising POI; and critiques of statistical modelling and economic analysis approaches to surrogacy.